To include your compound in the COVID-19 Resource Center, submit it here.

Jetrea ocriplasmin regulatory update

ThromboGenics said South Korea approved Jetrea ocriplasmin to treat vitreomacular adhesion (VMA), including when associated

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE